Antitumor effects of L-BLP25 Antigen-Specific tumor immunotherapy in a novel human MUC1 transgenic lung cancer mouse model

BACKGROUND: L-BLP25 antigen-specific cancer immunotherapeutic agent is currently in phase III clinical trials for non-small cell lung cancer. Using a novel human MUC1 transgenic (hMUC1.Tg) lung cancer mouse model, we evaluated effects of L-BLP25 combined with low-dose cyclophosphamide (CPA) pretreat...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Wurz, Gregory T, Gutierrez, Audrey M, Greenberg, Brittany E, Vang, Daniel P, Griffey, Stephen M, Kao, Chiao-Jung, Wolf, Michael, DeGregorio, Michael W
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2013
Matèries:
Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3605365/
https://ncbi.nlm.nih.gov/pubmed/23496860
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1479-5876-11-64
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars